CBIO - GLYCOMIMETICS INC

12.07
0.740   6.131%

Share volume: 159,573
Last Updated: 03-06-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.14%

PREVIOUS CLOSE
CHG
CHG%
$11.33
0.74
0.07%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
21%
Profitability 25%
Dept financing 2%
Liquidity 50%
Performance 15%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
7.86%
1 Month
27.72%
3 Months
-8.35%
6 Months
-6.80%
1 Year
4,524.52%
2 Year
342.12%
Key data
Stock price
$12.07
P/E Ratio 
0.00
DAY RANGE
$11.00 - $12.43
EPS 
-$10.40
52 WEEK RANGE
$0.15 - $21.40
52 WEEK CHANGE
$4,524.52
MARKET CAP 
164.765 M
YIELD 
N/A
SHARES OUTSTANDING 
27.557 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-08-2025
BETA 
0.45
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$115,633
AVERAGE 30 VOLUME 
$181,184
Company detail
CEO: Harout Semerjian
Region: US
Website: glycomimetics.com
Employees: 50
IPO year: 2014
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

GlycoMimetics, Inc. focuses on the discovery and development of novel glycomimetic drugs. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as in phase 3 trial to treat relapsed/refractory AML.

Recent news